Differential expression of folate receptor in pituitary adenomas

Cancer Research

Volumn 63, Issue 14, 2003, Pages 4218-4224

  Evans, Chheng Orn ^a   Reddy, Prasad ^b   Brat, Daniel J ^a   O'Neill, Eric B ^a   Craige, Branch ^a   Stevens, Victoria L ^a   Oyesiku, Nelson M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CORTICOTROPIN; FOLATE RECEPTOR; FOLIC ACID RECEPTOR ALPHA; GROWTH HORMONE; MESSENGER RNA; PROLACTIN; RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CARCINOGENESIS; CELL GROWTH; CLINICAL ARTICLE; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HYPOPHYSIS ADENOMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; WESTERN BLOTTING;

ADENOMA; ADULT; AGED; BLOTTING, WESTERN; CARRIER PROTEINS; CHILD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0042172981     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Greenman, Y., and Melmed, S. Diagnosis and management of nonfunctioning pituitary tumors. Annu. Rev. Med., 47: 95-106, 1996.
2. Asa, S. (ed.). Tumors of the Pituitary Gland. Washington, DC: Armed Forces Institute of Pathology, 1998.
3. Asa, S. L., and Kovacs, K. Clinically non-functioning human pituitary adenomas. Can. J. Neurol. Sci., 19: 228-235, 1992.
4. Asa, S. L., and Ezzat, S. The cytogenesis and pathogenesis of pituitary adenomas. Endocr. Rev., 19: 798-827, 1998.
5. Black, P. M., Hsu, D. W., Klibanski, A., Kliman, B., Jameson, J. L., Ridgway, E. C., Hedley-Whyte, E. T., and Zervas, N. T. Hormone production in clinically nonfunctioning pituitary adenomas. J. Neurosurg., 66: 244-250, 1987.
6. Katznelson, L., Alexander, J. M., and Klibanski, A. Clinical review 45: clinically nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab., 76: 1089-1094, 1993.
7. Asa, S. L., Cheng, Z., Ramyar, L., Singer, W., Kovacs, K., Smyth, H. S., and Muller, P. Human pituitary null cell adenomas and oncocytomas in vitro: effects of adenohypophysiotropic hormones and gonadal steroids on hormone secretion and tumor cell morphology. J. Clin. Endocrinol. Metab., 74: 1128-1134, 1992.
8. Yamada, S., Asa, S. L., Kovacs, K., Muller, P., and Smyth, H. S. Analysis of hormone secretion by clinically nonfunctioning human pituitary adenomas using the reverse hemolytic plaque assay. J. Clin. Endocrinol. Metab., 68: 73-80, 1989.
9. Herman, V., Fagin, J., Gonsky, R., Kovacs, K., and Melmed, S. Clonal origin of pituitary adenomas. J. Clin. Endocrinol. Metab., 71: 1427-1433, 1990.
10. Alexander, J. M., Biller, B. M., Bikkal, H., Zervas, N. T., Arnold, A., and Klibanski, A. Clinically nonfunctioning pituitary tumors are monoclonal in origin. J. Clin. Investig., 86: 336-340, 1990.
11. Evans, C. O., Brown, M. R., Parks, J. S., and Oyesiku, N. M. Screening for MEN1 tumor suppressor gene mutations in sporadic pituitary tumors. J. Endocrinol. Investig., 23: 304-309, 2000.
12. Asa, S. L., Somers, K., and Ezzat, S. The MEN-1 gene is rarely down-regulated in pituitary adenomas. J. Clin. Endocrinol. Metab., 83: 3210-3212, 1998.
13. Satta, M. A., Korbonits, M., Jacobs, R. A., Bolden-Dwinfour, D. A., Kaltsas, G. A., Vangeli, V., Adams, E., Fahlbusch, R., and Grossman, A. B. Expression of menin gene mRNA in pituitary tumours. Eur. J. Endocrinol., 140: 358-361, 1999.
14. Farrell, W. E., Simpson, D. J., Bicknell, J., Magnay, J. L., Kyrodimou, E., Thakker, R. V., and Clayton, R. N. Sequence analysis and transcript expression of the MEN1 gene in sporadic pituitary tumours. Br. J. Cancer, 80: 44-50, 1999.
15. Orr, R. B., Kreisler, A. R., and Kamen, B. A. Similarity of folate receptor expression in UMSCC 38 cells to squamous cell carcinoma differentiation markers. J. Natl. Cancer Inst. (Bethesda), 87: 299-303, 1995.
16. Shimon, I., and Melmed, S. Genetic basis of endocrine disease: pituitary tumor pathogenesis. J. Clin. Endocrinol. Metab., 82: 1675-1681, 1997.
17. Spada, A., and Faglia, G. G-protein dysfunction in pituitary tumors. In: S. Melmed (ed.), Oncogenesis and Molecular Biology of Pituitary Tumors, Vol. 20, pp. 108-121. Basel: Karger, 1996.
18. Gittoes, N. J. Current perspectives on the pathogenesis of clinically non-functioning pituitary tumours. J. Endocrinol., 157: 177-186, 1998.
19. Gittoes, N. J., McCabe, C. J., Sheppard, M. C., and Franklyn, J. A. Retinoid X receptor gamma mRNA expression is reduced in recurrent non-functioning pituitary adenomas. Clin. Endocrinol., 48: 527, 1998.
20. Gittoes, N. J., McCabe, C. J., Verhaeg, J., Sheppard, M. C., and Franklyn, J. A. Thyroid hormone and estrogen receptor expression in normal pituitary and nonfunctioning tumors of the anterior pituitary. J. Clin. Endocrinol. Metab., 82: 1960-1967, 1997.
21. Gittoes, N. J., McCabe, C. J., Verhaeg, J., Sheppard, M. C., and Franklyn, J. A. Retinoid X receptor expression in the normal pituitary and clinically 'non-functioning' pituitary tumours. Clin. Endocrinol., 48: 425-433, 1998.
22. Chaidarun, S. S., Eggo, M. C., Sheppard, M. C., and Stewart, P. M. Expression of epidermal growth factor (EGF), its receptor, and related oncoprotein (erbB-2) in human pituitary tumors and response to EGF in vitro. Endocrinology, 135: 2012-2021, 1994.
23. Evans, C. O., Young, A. N., Brown, M. R., Brat, D. J., Parks, J. S., Neish, A. S., and Oyesiku, N. M. Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. J. Clin. Endocrinol. Metab., 86: 3097-3107, 2001.
24. Antony, A. C. The biological chemistry of folate receptors. Blood, 79: 2807-2820, 1992.
25. Pizzomo, G., Cashmore, A. R., Moroson, B. A., Cross, A. D., Smith, A. K., Marling-Cason, M., Kamen, B. A., and Beardsley, G. P. 5, 10-Dideazatetrahydrofolic acid (DDATHF) transport in CCRF-CEM and MA104 cell lines. J. Biol. Chem., 268: 1017-1023, 1993.
26. Ragoussis, J., Senger, G., Trowsdale, J., and Campbell, I. G. Genomic organization of the human folate receptor genes on chromosome 11q13. Genomics, 14: 423-430, 1992.
27. Weitman, S. D., Weinberg, A. G., Coney, L. R., Zurawski, V. R., Jennings, D. S., and Kamen, B. A. Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res., 52: 6708-6711, 1992.
28. Weitman, S., Anderson, R. G. W., and Kamen, B. A. Folate binding proteins. In: K. Dakshinamurti (ed.), Vitamin Receptors: Vitamins As Ligands in Cell Communication, pp. 107-136. Cambridge: University Press, 1994.
29. Kamen, B. A. Folate receptor-α. In: E. J. Massaro and J. M. Rogers (eds.), Folate and Human Development, pp. 117-135. Totowa, NJ: Humana Press, 2002.
30. Ross, J. F., Chaudhuri, P. K., and Ratnam, M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer, 73: 2432-2443, 1994.
31. Kane, M. A., Portillo, R. M., Elwood, P. C., Antony, A. C., and Kolhouse, J. F. The influence of extracellular folate concentration on methotrexate uptake by human KB cells. Partial characterization of a membrane-associated methotrexate binding protein. J. Biol. Chem., 261: 44-49, 1986.
32. Mathias, C. J., and Green, M. A. A kit formulation for preparation of [(111)In]In-DTPA-folate, a folate-receptor-targeted radiopharmaceutical. Nucl. Med. Biol., 25: 585-587, 1998.
33. Mathias, C. J., Wang, S., Waters, D. J., Turek, J. J., Low, P. S., and Green, M. A. Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical. J. Nucl. Med., 39: 1579-1585, 1998.
34. Lacey, S. W., Sanders, J. M., Rothberg, K. G., Anderson, R. G., and Kamen, B. A. Complementary DNA for the folate binding protein correctly predicts anchoring to the membrane by glycosyl-phosphatidylinositol. J. Clin. Investig., 84: 715-720, 1989.
35. Douglas, J. T., Rogers, B. E., Rosenfeld, M. E., Michael, S. I., Feng, M., and Curiel, D. T. Targeted gene delivery by tropism-modified adenoviral vectors. Nat. Biotechnol., 14: 1574-1578, 1996.
36. Rettig, W., Cordon-Cardo, C., Koulos, J. P., Lewis, J. L., Jr., Oettgen, H. F., and Old, L. J. Cell surface antigens of human trophoblast and choriocarcinoma defined by monoclonal antibodies. Int. J. Cancer, 35: 469-475, 1985.
37. Toffoli, G., Cernigoi, C., Russo, A., Gallo, A., Bagnoli, M., and Boiocchi, M. Overexpression of folate binding protein in ovarian cancers. Int. J. Cancer, 74: 193-198, 1997.
38. Yan, W., and Ratnam, M. Preferred sites of glycosylphosphatidylinositol modification in folate receptors and constraints in the primary structure of the hydrophobic portion of the signal. Biochemistry, 34: 14594-14600, 1995.
39. Shen, F., Wang, H., Zheng, X., and Ratnam, M. Expression levels of functional folate receptors alpha and beta are related to the number of N-glycosylated sites. Biochem. J., 327: 759-764, 1997.
40. Roberts, S. J., Petropavlovskaja, M., Chung, K-N., Knight, C. B., and Elwood, P. C. Role of individual N-linked glycosylation sites in the function and intracellular transport of the human a folate receptor. Arch. Biochem. Biophys., 351: 227-235, 1998.
41. Matsue, H., Rothberg, K. G., Takashima, A., Kamen, B. A., Anderson, R. G. W., and Lacey, S. W. Folate receptor allows cells to grow in low concentrations of 5-methyltetrahydrofolate. Proc. Natl. Acad. Sci. USA, 89: 6006-6009, 1992.
42. Luhrs, C. A., Raskin, C. A., and Durbin, R. E. A. Transfection of a glycosylated phosphatidylinositol-anchored folate-binding protein complementary DNA provides cells with the ability to survive in low folate medium. J. Clin. Investig., 90: 840-847, 1992.
43. Bottero, F., Tomassetti, A., Canevari, S., Miotti, S., Menard, S., and Colnaghi, M. I. Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo. Cancer Res., 53: 5791-5796, 1993.
44. Holm, J., Hansen, S. I., Hoier-Madsen, M., Birn, H., and Helkjaer, P. E. High-affinity folate receptor in human ovary, serous ovarian adenocarcinoma, and ascites: radioligand binding mechanism, molecular size, ionic properties, hydrophobic domain, and immunoreactivity. Arch. Biochem. Biophys., 366: 183-191, 1999.
45. Goldman, I. D. The characteristics of the membrane transport of amethopterin and the naturally occurring folates. Ann. N. Y. Acad. Sci., 186: 400-422, 1971.
46. Lamers, C. H., Gratama, J. W., Warnaar, S. O., Stoter, G., and Bolhuis, R. L. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes. Int. J. Cancer, 60: 450-457, 1995.
47. Lu, Y., and Low, P. S. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev., 54: 675-693, 2002.
48. Wang, S., Luo, J., Lantrip, D. A., Waters, D. J., Mathias, C. J., Green, M. A., Fuchs, P. L., and Low, P. S. Design and synthesis of [111In]DTPA-folate for use as a tumor-targeted radiopharmaceutical. Bioconjug. Chem., 8: 673-679, 1997.
49. Toffoli, G., Russo, A., Gallo, A., Cernigoi, C., Miotti, S., Sorio, R., Tumolo, S., and Boiocchi, M. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int. J. Cancer, 79: 121-126, 1998.